Some of the losses are down to pharma's broader problems: notably, President Trump's tariff and price-cut threats. But there ...

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

Mumbai: In a serious security and public health concern, several consignments of Novo Nordisk’s injectable medicines — ...

Viking Therapeutics (NASDAQ:VKTX), often touted as an attractive obesity play, shed more than a third of its value this week ...

FAT jabs can shrink your waistline but can they turbo-boost your bank balance? Rookie investor Megan Norman reveals how she ...

COMMENT: The monthly cost of a private prescription exceeding £300 from next month is worrying news for the half a million ...